NASDAQ:BIOCBiocept Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biocept Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.28 0.00 (-0.18 %) (As of 04/8/2020 11:24 AM ET) Add Compare Share Today's Range$0.27Now: $0.28▼$0.2850-Day Range$0.24MA: $0.36▼$0.7852-Week Range$0.21Now: $0.28▼$2.11Volume59,771 shsAverage Volume13.55 million shsMarket Capitalization$30.27 millionP/E RatioN/ADividend YieldN/ABeta0.08 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBiocept has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, Biocept has a potential upside of 259.1% from its current price of $0.28.Amount of Analyst CoverageBiocept has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesBiocept has received 324 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiocept has received 343 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiocept has received 51.42% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote “Outperform” if you believe BIOC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiocept does not currently pay a dividend.Dividend GrowthBiocept does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biocept insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.32% of the stock of Biocept is held by insiders.Percentage Held by InstitutionsOnly 1.11% of the stock of Biocept is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Biocept is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biocept is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiocept has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.18 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOC Previous Symbol CUSIPN/A CIK1044378 Webhttp://www.biocept.com/ Phone858-320-8200Debt Debt-to-Equity Ratio0.09 Current Ratio2.50 Quick Ratio2.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.53 million Price / Sales5.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book1.16Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-25,140,000.00 Net Margins-455.14% Return on Equity-218.69% Return on Assets-135.91%Miscellaneous Employees95 Outstanding Shares108,707,000Market Cap$30.27 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive BIOC News and Ratings via Email Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BIOC Rates by TradingView Biocept (NASDAQ:BIOC) Frequently Asked Questions How has Biocept's stock been impacted by COVID-19 (Coronavirus)? Biocept's stock was trading at $0.3769 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOC stock has decreased by 26.1% and is now trading at $0.2785. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Biocept? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biocept. When is Biocept's next earnings date? Biocept is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Biocept. How were Biocept's earnings last quarter? Biocept Inc (NASDAQ:BIOC) posted its earnings results on Wednesday, March, 25th. The medical research company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.10. The medical research company had revenue of $1.78 million for the quarter. Biocept had a negative net margin of 455.14% and a negative return on equity of 218.69%. View Biocept's earnings history. What price target have analysts set for BIOC? 1 Wall Street analysts have issued 1 year target prices for Biocept's shares. Their forecasts range from $1.00 to $1.00. On average, they expect Biocept's share price to reach $1.00 in the next year. This suggests a possible upside of 259.1% from the stock's current price. View analysts' price targets for Biocept. Has Biocept been receiving favorable news coverage? News stories about BIOC stock have trended very negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biocept earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutBiocept. Who are some of Biocept's key competitors? Some companies that are related to Biocept include Enzo Biochem (ENZ), Anpac Bio-Medical Science (ANPC), Celcuity (CELC), Psychemedics (PMD), OpGen (OPGN), Miragen Therapeutics (MGEN), Avant Diagnostics (AVDX), CBA Florida (CBAI), PotNetwork (POTN), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). What other stocks do shareholders of Biocept own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include Walmart (WMT), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Onconova Therapeutics (ONTX), Actinium Pharmaceuticals (ATNM) and Kadmon (KDMN). Who are Biocept's key executives? Biocept's management team includes the following people: Mr. Michael W. Nall, CEO, Pres & Director (Age 56)Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)Dr. Soon Kap Hahn Ph.D., FounderMr. Pavel Tsinberg, Director of Technology Devel. What is Biocept's stock symbol? Biocept trades on the NASDAQ under the ticker symbol "BIOC." How do I buy shares of Biocept? Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Biocept's stock price today? One share of BIOC stock can currently be purchased for approximately $0.28. How big of a company is Biocept? Biocept has a market capitalization of $30.27 million and generates $5.53 million in revenue each year. Biocept employs 95 workers across the globe. View additional information about Biocept. What is Biocept's official website? The official website for Biocept is http://www.biocept.com/. How can I contact Biocept? Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: What is the LIBOR?
